{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography-computed+tomography+%28PET%2FCT%29&page=41", "query": { "intervention": "Positron emission tomography-computed tomography (PET/CT)", "page": 41 }, "page_size": 10 }, "pagination": { "page": 41, "page_size": 10, "total_count": 1507, "total_pages": 151, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography-computed+tomography+%28PET%2FCT%29&page=42&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography-computed+tomography+%28PET%2FCT%29&page=40&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T23:14:43.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05731440", "title": "Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "18F-Fluselenamyl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-11-18", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05731440" }, { "nct_id": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Colon Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Salivary Gland Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "HER2-Positive Breast Carcinoma", "Malignant Hepatobiliary Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Salivary Gland Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Colon Carcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 23, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704661" }, { "nct_id": "NCT02693860", "title": "Neoadjuvant J591 Treatment for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "huJ591", "type": "DRUG" }, { "name": "89Zr-J591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2016-02-04", "completion_date": "2020-02-02", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02693860" }, { "nct_id": "NCT04071223", "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Renal Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Kidney Medullary Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Papillary Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8", "Unclassified Renal Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2020-07-29", "completion_date": "2027-09-24", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 47, "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04071223" }, { "nct_id": "NCT05758493", "title": "Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis", "Transthyretin Amyloidosis" ], "interventions": [ { "name": "124I-Evuzamitide", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 150, "start_date": "2023-01-10", "completion_date": "2028-03-10", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05758493" }, { "nct_id": "NCT01964625", "title": "Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "PET-CT Scan", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-11", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2013-10-17", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01964625" }, { "nct_id": "NCT03427476", "title": "CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "CTT1057", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cancer Targeted Technology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-01-01", "completion_date": "2018-08-31", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03427476" }, { "nct_id": "NCT05556473", "title": "F-Tryptophan PET/CT in Human Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intracranial Glioma", "Metastatic Brain Tumor", "Breast Cancer", "Neuroendocrine Tumors", "Rectal Cancer" ], "interventions": [ { "name": "1-(2-[18F]FLUOROETHYL)-L-Tryptophan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-09-29", "completion_date": "2025-07-18", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05556473" }, { "nct_id": "NCT07061964", "title": "Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Photon Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2025-11-25", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 181, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07061964" }, { "nct_id": "NCT00858663", "title": "Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "intensity modulated radiation therapy", "type": "RADIATION" }, { "name": "RAD001 (everolimus) + Cisplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-03", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-07-25", "last_synced_at": "2026-10-16T23:14:43.365Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858663" } ] }